Association between allelic burden and risk of OS and relapse risk. (A) OS and (B) relapse incidence depending on the presence of allelic burden at day 21 after allogeneic HCT. (C) OS and (D) relapse incidence depending on the presence of allelic burden in 47 patients classified as intermediate risk based on 2017 ELN recommendations. (E) OS and (F) relapse incidence depending on the presence of allelic burden in 26 patients classified as poor risk based on 2017 ELN recommendations. Number of patients at risk for every 2 years is shown below each Kaplan-Meier curve.